The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Tirzepatide is approved for moderate-to-severe obstructive sleep apnea (OSA ... significant reductions in breathing disruptions and weight loss with tirzepatide. Nearly half of trial participants ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA). The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first ...

(Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly (NYSE:LLY)'s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to ...

has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound. In a news release published Dec. 20, the FDA stated that ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

Let Sleeping Babies Lie: Scientists Highlight Negative Impacts of Sleep Disruption on Early Brain Development Oct. 23, 2024 — Researchers show how sleep loss during early life impacts key ...